Literature DB >> 2844427

Current approaches to the development of vaccines effective against parainfluenza viruses.

B R Murphy.   

Abstract

Infection of infants and children with parainfluenza viruses can lead to serious lower respiratory tract disease. In order to review new information on the genetic organization, epidemiology, and immunobiology of these viruses and of respiratory syncytial virus, WHO, in conjunction with the National Institute of Allergy and Infectious Diseases, held a workshop in Bethesda, MD, USA, 4-5 May 1987. New data on the immunobiology and epidemiology of human parainfluenza 3 virus were presented that should facilitate the development of a vaccine against this pathogen.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844427      PMCID: PMC2491123     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  24 in total

1.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

2.  Biologic significance of the secretory A immunoglobulins.

Authors:  J A Bellanti
Journal:  Pediatrics       Date:  1971-11       Impact factor: 7.124

3.  The effects of monoclonal antibodies on biologic activities of structural proteins of Sendai virus.

Authors:  C Orvell; M Grandien
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

4.  Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers.

Authors:  B R Murphy; M L Clements; E L Tierney; R E Black; J Stienberg; R M Chanock
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

5.  Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine.

Authors:  T F Scott; D E Bonanno
Journal:  N Engl J Med       Date:  1967-08-03       Impact factor: 91.245

6.  Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2.

Authors:  M Tashiro; M Homma
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

7.  Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus.

Authors:  E Norrby; G Enders-Ruckle; V Meulen
Journal:  J Infect Dis       Date:  1975-09       Impact factor: 5.226

8.  Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters.

Authors:  F K Crookshanks; R B Belshe
Journal:  J Med Virol       Date:  1984       Impact factor: 2.327

9.  Pneumotropism of Sendai virus in relation to protease-mediated activation in mouse lungs.

Authors:  M Tashiro; M Homma
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

10.  Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers.

Authors:  R B Belshe; F K Hissom
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

View more
  12 in total

1.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 2.  Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease.

Authors:  Anne Moscona
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

3.  Molecular characterization of human parainfluenza virus type 1 in infants attending Mbagathi District Hospital, Nairobi, Kenya: a retrospective study.

Authors:  Joshua K Kiptinness; Eyako K Wurapa; Fred Wamunyokoli; Wallace D Bulimo
Journal:  Virus Genes       Date:  2013-08-17       Impact factor: 2.332

Review 4.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

Review 5.  Progress in the development of human parainfluenza virus vaccines.

Authors:  Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins
Journal:  Expert Rev Respir Med       Date:  2011-08       Impact factor: 3.772

6.  Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Emerito Amaro-Carambot; Sheila M Nolan; Stephanie Davis; Shenelle-Marie Wise; Caraline Higgins; Konrad Bradley; Olivia Kim; Reina Mayor; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2010-07-27       Impact factor: 3.616

7.  Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Authors:  Anne Schaap-Nutt; Margaret A Scull; Alexander C Schmidt; Brian R Murphy; Raymond J Pickles
Journal:  Vaccine       Date:  2010-02-20       Impact factor: 3.641

8.  Inhibition of human parainfluenza virus type 3 infection by novel small molecules.

Authors:  Hongxia Mao; Chandar S Thakur; Santanu Chattopadhyay; Robert H Silverman; Andrei Gudkov; Amiya K Banerjee
Journal:  Antiviral Res       Date:  2007-10-02       Impact factor: 5.970

9.  Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Authors:  Sheila M Nolan; Mario H Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian R Murphy; Anne Schaap-Nutt
Journal:  Vaccine       Date:  2007-07-03       Impact factor: 3.641

10.  Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2009-12-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.